Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment

Journal of Virology

Volumn 74, Issue 6, 2000, Pages 2584-2593

  Lifson, Jeffrey D ^a   Rossio, Jeffrey L ^a   Arnaout, Ramy ^b   Li, Li ^a   Parks, Thomas L ^a   Schneider, Douglas K ^a   Kiser, Rebecca F ^a   Coalter, Vicky J ^a   Walsh, Geneva ^a   Imming, Robert J ^a   Fisher, Bradley ^c   Flynn, Bernard M ^c   Bischofberger, Norbert ^d   Piatak Jr , Michael ^a   Hirsch, Vanessa M ^e   Nowak, Martin A ^b   Wodarz, Dominik ^b  

^a SAIC FREDERICK INC   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GILEAD SCIENCES   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOST RESISTANCE; IMMUNOREACTIVITY; MACACA; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; FEMALE; MACACA MULATTA; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VIRAL LOAD;

EID: 17344384248     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.6.2584-2593.2000     Document Type: Article

References (59)

1. Arthur, L. O., J. W. Bess, Jr., E. N. Chertova, J. L. Rossio, M. T. Esser, R. E. Benveniste, L. E. Henderson, and J. D. Lifson. 1998. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retroviruses 14(Suppl. 3):S311-S319.
2. Bachmann, M. F., T. M. Kundig, H. Hengartner, and R. M. Zinkernagel. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without " memory T cells"? Proc. Natl. Acad. Sci. USA 94:640-645.
3. Benveniste, R. E., R. W. Hill, L. J. Eron, U. M. Csaikl, W. B. Knott, L. E. Henderson, R. C. Sowder, K. Nagashima, and M. A. Gonda. 1990. Characterization of clones of HIV-1 HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein. J. Med. Primatol. 19:351-366.
4. Benveniste, R. E., S. T. Roodman, R. W. Hill, W. B. Knott, J. L. Fibas, M. G. Lewis, and G. A. Eddy. 1994. Infectivity of titered doses of simian immunodeficiency virus clone E11S inoculated intravenously into rhesus macaques. J. Med. Primatol. 23:83-88.
5. Bess, J. W., Jr., R. J. Gorelick, W. J. Bosche, L. E. Henderson, and L. O. Arthur. 1997. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230:134-144.
6. + CTL response. J. Exp. Med. 183:2129-2142.
7. + cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J. Virol. 72:7440-7449.
8. Chaffee, S., J. M. Leeds, T. J. Matthews, K. J. Weinhold, M. Skinner, D. P. Bolognesi, and M. S. Hershfield. 1988. Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. J. Exp. Med. 168:605-621.
9. Clerici, M., J. M. Levin, H. A. Kessler, A. Harris, J. A. Berzofsky, A. L. Landay, and G. M. Shearer. 1994. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 271:42-46.
10. 9a.Committee on Care and Use of Laboratory Animals. 1996. Guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources. National Research Council, Washington, D.C.
11. Decks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellman, S. Safrin, and J. O. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
12. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431-1437.
13. Dittmer, U., D. M. Brooks, and J. K. J. Hasenkrug. 1999. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat. Med. 4:1890-1893.
14. Ehl, S., P. Klenerman, P. Aichele, H. Hengartner, and R. M. Zinkernagel. 1997. A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. Eur. J. Immunol. 27: 3404-3413.
15. + T cells provides a mechanism for lifelong persistence of HIV-1 in patients on effective combination therapy. Nat. Med. 5:512-517.
16. Goldstein, S., W. R. Elkins, W. T. London, A. Hahn, R. Goeken, J. E. Martin, and V. M. Hirsch. 1994. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J. Med. Primatol. 23:75-82.
17. Gurtman, A., F. Borrego, and M. E. Klotman. 1998. Management of antiretroviral therapy. Semin. Nephrol. 18:459-480.
18. Havlir, D. V., and J. M. Lange. 1998. New antiretrovirals and new combinations. AIDS 12(Suppl. A):S165-S174.
19. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
20. Hirsch, V. M., and J. D. Lifson. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment and prevention. Adv. Pharmacol., in press.
21. + T cells. J. Virol. 65:220-224.
22. Johnson, R. P., J. D. Lifson, S. C. Czajak, K. S. Cole, K. H. Manson, R. Glickman, J. Yang, D. C. Montefiori, R. Montelaro, M. S. Wyand, and R. C. Desrosiers. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73:4952-4961.
23. Johnson, R. P., and R. C. Desrosiers. 1998. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10: 436-443.
24. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188: 2199-2204.
25. Kalams, S. A., P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg, and B. D. Walker. 1999. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721-6728.
26. Kalams, S. A., S. P. Buchbinder, E. S. Rosenberg, J. M. Billingsley, D. S. Colbert, N. G. Jones, A. K. Shea, A. K. Trocha, and B. D. Walker. 1999. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73: 6715-6720.
27. Kundig, T. M., M. F. Bachmann, P. S. Ohashi, H. Pircher, H. Hengartner, and R. M. Zinkernagel. 1996. On T cell memory: arguments for antigen dependence. Immunol. Rev. 150:63-90.
28. + T cells. Immunol. Today 17:217-224.
29. Lifson, J. D., M. Nowak, S. Goldstein, J. L. Rossio, A. Kinter, G. Vasquez, T. A. Willrout, C. Brown, D. Schneider, L. Wahl, A. Lloyd, W. R. Elkins, A. S. Fauci, and V. M. Hirsch. 1997. The extent of early viral replication is a critical determinant of the natural history of AIDS virus infection. J. Virol. 75:9508-9514.
30. Lisziewicz, J., E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, and F. Lori. 1999. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340:1683-1684. (Letter.)
31. Nowak, M. A., A. L. Lloyd, G. M. Vasquez, T. A. Wiltrout, L. M. Wahl, N. Bischofberger, J. Williams, A. Kinter, A. S. Fauci, V. M. Hirsch, and J. D. Lifson. 1997. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71:7518-7525.
32. Rosenberg, E. S., and B. D. Walker. 1998. HIV-type 1-specific helper T cells: a critical host defense. AIDS Res. Hum. Retroviruses 14(Suppl. 2):S143-S147.
33. - T cell responses associate with control of viremia. Science 278:1447-1450.
34. Rosenberg, E. S., L. La Rosa, T. Flynn, G. Robbins, and B. D. Walker. 1999. Characterization of HIV-1 specific T helper cells in acute and chronic infection. Immunol. Lett. 6:89-93.
35. Rossio, J., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. J. Sattentau, L. O. Arthur, L. E. Henderson, and J. D. Lifson. 1988. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
36. Ruprecht, R. M., and R. Bronson. 1994. Chemoprevention of retroviral infection: success is determined by virus inoculum strength and cellular immunity. DNA Cell. Biol. 13:59-66.
37. Ruprecht, R. M., T. W. Baba, R. Rasmussen, Y. Hu, and P. L. Sharma. 1996. Murine and simian retrovirus models: the threshold hypothesis. AIDS 10(Suppl. A):S33-S40.
38. Ruprecht, R. M., T. C. Chou, F. Chipty, M. G. Sosa, S. Mullaney, L. O'Brien, and D. Rosas. 1990. Interferon-alpha and 3′-azido′3′deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. J. Acquired Immune Defic. Syndr. 3:591-600.
39. Ruprecht, R. M., S. Mullaney, L. D. Bernard, M. A. Gama Sosa, R. C. Hom, and R. W. Finberg. 1990. Vaccination with a live retrovirus: the nature of the protective immune responses. Proc. Natl. Acad. Sci. USA 84:5558-5562.
40. Staprans, S. I., P. J. Dailey, A. Rosenthal, C. Horton, R. M. Grant, N. Lerche, and M. B. Feinberg. 1999. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J. Virol. 73:4829-4839.
41. Suryanarayana, K., T. A. Wiltrout, G. M. Vasquez, V. M. Hirsch, and J. D. Lifson. 1998. Plasma SIV RNA viral load by real time quantification of product generation in RT PCR. AIDS Res. Hum. Retroviruses 14:183-189.
42. Thomsen, A. R., J. Johansen, O. Marker, and J. P. Christensen. 1997. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus infected MHC class II deficient mice and B cell deficient mice. J. Immunol. 157:3074-3080.
43. Thomsen, A. R., A. Nansen, J. P. Christensen, S. O. Andreasen, and O. Marker. 1998. CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. J. Immunol. 161: 4583-4590.
44. Tsai, C. C., P. Emau, K. E. Follis, T. W. Beck, R. E. Benveniste, N. Bischofberger, J. D. Lifson, and W. R. Morton. 1998. Effectiveness of postinoculation 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J. Virol. 75:4265-4273.
45. Tsai, C. C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischofberger, and P. J. Dailey. 1997. Effects of 9-[2-(R)-(phosphonomethoxy)propyl]adenine monotherapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13:707-712.
46. Tsai, C. C., K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macacques by 9-[2-(R)-(phosphonomethoxy)propyl]adenine. Science 270:1121-1122.
47. Van Rompay, K. K., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(R)-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
48. Van Rompay, K. K., C. J. Berardi, N. L. Aguirre, N. Bischofberger, P. S. Lietman, N. C. Pedersen, and M. L. Marthas. 1998. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 12:F79-F83.
49. Van Rompay, K. K., P. J. Dailey, R. P. Tarara, D. R. Canrield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pederson, and M. L. Marthas. 1999. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73: 2947-2955.
50. Van Rompay, K. K., M. L. Marthas, J. D. Lifson, C. J. Berardi, G. M. Vasquez, E. Agatep, Z. A. Dehqanzada, K. C. Cundy, N. Bischofberger, and N. C. Pedersen. 1998. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res. Hum. Retroviruses 14:761-763.
51. Walker, B. D., E. S. Rosenberg, C. M. Hay, N. Basgoz, and O. O. Yang. 1998. Immune control of HIV-1 replication. Adv. Exp. Med. Biol. 452:159-167.
52. Watson, A., J. Ranchalis, B. Travis, J. McClure, W. Sutton, P. R. Johnson, S.-L. Hu, and N. L. Haigwood. 1997. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71:284-290.
53. + cell decline in HIV type 2-infected macaques. AIDS Res. Hum. Retroviruses 13:1375-1381.
54. Wodarz, D., P. Klenerman, and M. A. Nowak. 1998. Dynamics of cytotoxic T-lymphocyte exhaustion. Proc. R. Soc. Lond. B 265:191-203.
55. Wodarz, D., and M. A. Nowak. Immune responses and viral phenotype: do replication rate and the cytopathogenicity influence virus load? J. Theor. Med., in press.
56. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.
57. Zidek, Z., A. Holy, and D. Frankova. 1997. Immunomodulatory properties of antiviral acyclic nucleotide analogues: cytokine stimulatory and nitric oxide costimulatory effects. Int. J. Immunopharmacol. 19:587-597.
58. Zidek, Z., A. Holy, and D. Frankova. 1997. Antiretroviral agent 9-[2-(R)-(phosphonomethoxy)propyl]adenine stimulates cytokine and nitric oxide production. Eur. J. Pharmacol. 331:245-252.
59. Zinkernagel, R. M. 1997. Immunology and immunity studied with viruses. Ciba Found. Symp. 204:105-125.